TFEB and kidney neoplasm: Additionally, TSC1/2 alterations have been described in novel and emerging renal tumor subtypes including ESC-RCC, eosinophilic vacuolated tumors, TFEB-altered RCC, low-grade oncocytic tumors (LOT), and eosinophilic vacuolated tumors (EVT) [75–78].